Cargando…
Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy
BACKGROUND: To retrospectively review the outcome of patients with primary or secondary oligometastatic lung cancer, treated with hypofractionated Tomotherapy. METHODS: Between April 2007 and June 2011, a total of 33 patients with oligometastatic intrapulmonary lesions underwent hypofractionated rad...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552755/ https://www.ncbi.nlm.nih.gov/pubmed/23268786 http://dx.doi.org/10.1186/1748-717X-7-222 |
_version_ | 1782256715804180480 |
---|---|
author | Chang, Heng-Jui Ko, Hui-Ling Lee, Cheng-Yen Wu, Ren-Hong Yeh, Yu-Wung Jiang, Jiunn-Song Kao, Shang-Jyh Chi, Kwan-Hwa |
author_facet | Chang, Heng-Jui Ko, Hui-Ling Lee, Cheng-Yen Wu, Ren-Hong Yeh, Yu-Wung Jiang, Jiunn-Song Kao, Shang-Jyh Chi, Kwan-Hwa |
author_sort | Chang, Heng-Jui |
collection | PubMed |
description | BACKGROUND: To retrospectively review the outcome of patients with primary or secondary oligometastatic lung cancer, treated with hypofractionated Tomotherapy. METHODS: Between April 2007 and June 2011, a total of 33 patients with oligometastatic intrapulmonary lesions underwent hypofractionated radiotherapy by Tomotherapy along with appropriate systemic therapy. There were 24 primary, and 9 secondary lung cancer cases. The radiation doses ranged from 4.5 to 7.0 Gy per fraction, multiplied by 8–16 fractions. The median dose per fraction was 4.5 Gy (range, 4.5-7.0 Gy), and the median total dose was 49.5 Gy (range, 45–72 Gy). The median estimated biological effective dose at 10 Gy (BED(10)) was 71.8 Gy (range, 65.3–119.0 Gy), and that at 3 Gy (BED(3)) was 123.8 Gy (range, 112.5–233.3 Gy). The mean lung dose (MLD) was constrained mainly under 1200 cGy. The median gross tumor volume (GTV) was 27.9 cm(3) (range: 2.5–178.1 cm(3)). RESULTS: The median follow-up period was 25.8 months (range, 3.0–60.7 months). The median overall survival (OS) time was 32.1 months for the 24 primary lung cancer patients, and >40 months for the 9 metastatic lung patients. The median survival time of the patients with extra-pulmonary disease (EPD) was 11.2 months versus >50 months (not reached) in the patients without EPD (p < 0.001). Those patients with smaller GTV (≦27.9 cm(3)) had a better survival than those with larger GTV (>27.9 cm(3)): >40 months versus 12.85 months (p = 0.047). The patients with ≦2 lesions had a median survival >40 months, whereas those with ≧3 lesions had 26 months (p = 0.065). The 2-year local control (LC) rate was 94.7%. Only 2 patients (6.1%) developed ≧grade 3 radiation pneumonitis. CONCLUSION: Using Tomotherapy in hypofractionation may be effective for selected primary or secondary lung oligometastatic diseases, without causing significant toxicities. Pulmonary oligometastasis patients without EPD had better survival outcomes than those with EPD. Moreover, GTV is more significant than lesion number in predicting survival. |
format | Online Article Text |
id | pubmed-3552755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35527552013-01-28 Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy Chang, Heng-Jui Ko, Hui-Ling Lee, Cheng-Yen Wu, Ren-Hong Yeh, Yu-Wung Jiang, Jiunn-Song Kao, Shang-Jyh Chi, Kwan-Hwa Radiat Oncol Research BACKGROUND: To retrospectively review the outcome of patients with primary or secondary oligometastatic lung cancer, treated with hypofractionated Tomotherapy. METHODS: Between April 2007 and June 2011, a total of 33 patients with oligometastatic intrapulmonary lesions underwent hypofractionated radiotherapy by Tomotherapy along with appropriate systemic therapy. There were 24 primary, and 9 secondary lung cancer cases. The radiation doses ranged from 4.5 to 7.0 Gy per fraction, multiplied by 8–16 fractions. The median dose per fraction was 4.5 Gy (range, 4.5-7.0 Gy), and the median total dose was 49.5 Gy (range, 45–72 Gy). The median estimated biological effective dose at 10 Gy (BED(10)) was 71.8 Gy (range, 65.3–119.0 Gy), and that at 3 Gy (BED(3)) was 123.8 Gy (range, 112.5–233.3 Gy). The mean lung dose (MLD) was constrained mainly under 1200 cGy. The median gross tumor volume (GTV) was 27.9 cm(3) (range: 2.5–178.1 cm(3)). RESULTS: The median follow-up period was 25.8 months (range, 3.0–60.7 months). The median overall survival (OS) time was 32.1 months for the 24 primary lung cancer patients, and >40 months for the 9 metastatic lung patients. The median survival time of the patients with extra-pulmonary disease (EPD) was 11.2 months versus >50 months (not reached) in the patients without EPD (p < 0.001). Those patients with smaller GTV (≦27.9 cm(3)) had a better survival than those with larger GTV (>27.9 cm(3)): >40 months versus 12.85 months (p = 0.047). The patients with ≦2 lesions had a median survival >40 months, whereas those with ≧3 lesions had 26 months (p = 0.065). The 2-year local control (LC) rate was 94.7%. Only 2 patients (6.1%) developed ≧grade 3 radiation pneumonitis. CONCLUSION: Using Tomotherapy in hypofractionation may be effective for selected primary or secondary lung oligometastatic diseases, without causing significant toxicities. Pulmonary oligometastasis patients without EPD had better survival outcomes than those with EPD. Moreover, GTV is more significant than lesion number in predicting survival. BioMed Central 2012-12-27 /pmc/articles/PMC3552755/ /pubmed/23268786 http://dx.doi.org/10.1186/1748-717X-7-222 Text en Copyright ©2012 Chang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Chang, Heng-Jui Ko, Hui-Ling Lee, Cheng-Yen Wu, Ren-Hong Yeh, Yu-Wung Jiang, Jiunn-Song Kao, Shang-Jyh Chi, Kwan-Hwa Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title_full | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title_fullStr | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title_full_unstemmed | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title_short | Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy |
title_sort | hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using tomotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552755/ https://www.ncbi.nlm.nih.gov/pubmed/23268786 http://dx.doi.org/10.1186/1748-717X-7-222 |
work_keys_str_mv | AT changhengjui hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT kohuiling hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT leechengyen hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT wurenhong hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT yehyuwung hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT jiangjiunnsong hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT kaoshangjyh hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy AT chikwanhwa hypofractionatedradiotherapyforprimaryorsecondaryoligometastaticlungcancerusingtomotherapy |